Anti cd20 clone 5d2

Manufactured by Genentech

Anti-CD20 (clone 5D2) is a monoclonal antibody that binds to the CD20 antigen. It is a laboratory reagent used for research purposes.

Automatically generated - may contain errors

Lab products found in correlation

Igg2a, by BioXCell (1 mentions) Diphtheria toxin, by Merck Group (1 mentions) Anti il 17a clone 17f3, by BioXCell (1 mentions) Anti cd25 clone pc 61, by BioXCell (1 mentions) Mouse igg1 clone mopc 21, by BioXCell (1 mentions)

2 protocols using anti cd20 clone 5d2

Generating Mixed Bone Marrow Chimeras

Check if the same lab product or an alternative is used in the 5 most similar protocols

To generate mixed bone marrow (BM) chimeras, lethally irradiated (11 Gy) Rag1^–/– mice were reconstituted with a 1:1 mixture of 2.5 × 10⁶ WT (CD45.1⁺) and 2.5 × 10⁶Stim1/2^Foxp3 (CD45.2⁺) BM and analyzed 10 weeks after reconstitution (see Fig. 6c). B cell depletion in 2–3-week-old WT and Stim1/2^Foxp3 mice was carried out by i.p. injection of 1 mg anti-CD20 (clone 5D2, Genentech) or isotype control (IgG2a, BioXCell). Successful ablation of B cells was confirmed 4 days later followed by hematological analyses (RBCs, hemoglobin levels, and hematocrit) 3–4 weeks later. To test the presence of anti-RBC autoantibodies, 250 µl pooled serum from WT or Stim1/2^Foxp3 mice was transferred retro-orbitally into WT recipient mice followed by hematological analyses (RBCs, hemoglobin levels and hematocrit) 3 days later (see Fig. 5b).

Vaeth M., Wang Y.H., Eckstein M., Yang J., Silverman G.J., Lacruz R.S., Kannan K, & Feske S. (2019). Tissue resident and follicular Treg cell differentiation is regulated by CRAC channels. Nature Communications, 10, 1183.

+ Open protocol

+ Expand

Pig Islet Transplantation Immunomodulation

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

ECDI-treated pig splenocytes were prepared as described(18 (link)). 10⁸ ECDI-SP in 200μl PBS were injected on days −7 and +1, with day 0 being the day of islet transplantation. In recipients treated with anti-CD20, 250 μg of anti-CD20 (clone 5D2; Genentech) was administrated i.v. on days −9 and 0 in recipients receiving pig ECDI-SP, or day 0 in recipients not receiving pig ECDI-SP. The additional dose of anti-CD20 on day −9 for pig ECDI-SP-treated recipients was given to inhibit the induction of anti-xenogeneic antibodies by xenogeneic ECDI-SP itself as we have shown previously(30 (link)). In selected groups, rapamycin (rapa, 1mg/kg daily) was administrated i.p. from day −8 to +10. Anti-IL-17A (clone 17F3; BioXCell) or mouse IgG1 (clone MOPC-21; BioXCell) was administrated at 100 μg/day i.p. from day 0 to 13. Anti-GM-CSFR (clone CAM3003) was injected at 600 μg/2 days i.p. from day 0 to 20 based on published report using this antibody(32 (link)). Anti-CD25 (clone PC-61, BioXCell) was injected at 0.5 mg/dose on day −9 and −7. Diphtheria toxin (Sigma) was dissolved in dH₂O, and injected i.p. at 10 μg/kg in triple therapy-treated and pig islet-transplanted B6.Foxp3-DTR/EGFP mice on days −9, −8, −6, −4, −2 and 0, with day 0 being the day of pig islet transplantation.

Kang H.K., Wang S., Dangi A., Zhang X., Singh A., Zhang L., Rosati J.M., Suarez-Pinzon W., Deng X., Chen X., Thorp E.B., Hering B.J., Miller S.D, & Luo X. (2017). Differential role of B cells and IL-17 versus IFN-γ during early and late rejection of pig islet xenografts in mice. Transplantation, 101(8), 1801-1810.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!